Yang Chen-Fu, Naguib Tary, Yang Su-Ju, Nasr Eman, Jorba Jaume, Ahmed Nahed, Campagnoli Ray, van der Avoort Harrie, Shimizu Hiroyuki, Yoneyama Tetsuo, Miyamura Tatsuo, Pallansch Mark, Kew Olen
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Virol. 2003 Aug;77(15):8366-77. doi: 10.1128/jvi.77.15.8366-8377.2003.
From 1988 to 1993, 30 cases of poliomyelitis associated with poliovirus type 2 were found in seven governorates of Egypt. Because many of the cases were geographically and temporally clustered and because the case isolates differed antigenically from the vaccine strain, it was initially assumed that the cases signaled the continued circulation of wild type 2 poliovirus. However, comparison of sequences encoding the major capsid protein, VP1 (903 nucleotides), revealed that the isolates were related (93 to 97% nucleotide sequence identity) to the Sabin type 2 oral poliovirus vaccine (OPV) strain and unrelated (<82% nucleotide sequence identity) to the wild type 2 polioviruses previously indigenous to Egypt (last known isolate: 1979) or to any contemporary wild type 2 polioviruses found elsewhere. The rate and pattern of VP1 divergence among the circulating vaccine-derived poliovirus (cVDPV) isolates suggested that all lineages were derived from a single OPV infection that occurred around 1983 and that progeny from the initiating infection circulated for approximately a decade within Egypt along several independent chains of transmission. Complete genomic sequences of an early (1988) and a late (1993) cVDPV isolate revealed that their 5' untranslated region (5' UTR) and noncapsid- 3' UTR sequences were derived from other species C enteroviruses. Circulation of type 2 cVDPVs occurred at a time of low OPV coverage in the affected communities and ceased when OPV coverage rates increased. The potential for cVDPVs to circulate in populations with low immunity to poliovirus has important implications for current and future strategies to eradicate polio worldwide.
1988年至1993年期间,埃及七个省份发现了30例与2型脊髓灰质炎病毒相关的脊髓灰质炎病例。由于许多病例在地理和时间上呈聚集性,且病例分离株在抗原性上与疫苗株不同,最初推测这些病例表明野生型2型脊髓灰质炎病毒仍在持续传播。然而,对编码主要衣壳蛋白VP1(903个核苷酸)的序列进行比较后发现,这些分离株与Sabin 2型口服脊髓灰质炎疫苗(OPV)株相关(核苷酸序列同一性为93%至97%),与埃及先前本土的野生型2型脊髓灰质炎病毒(最后一次已知分离株:1979年)或其他地方发现的任何当代野生型2型脊髓灰质炎病毒无关(核苷酸序列同一性<82%)。循环疫苗衍生脊髓灰质炎病毒(cVDPV)分离株中VP1的分化速率和模式表明,所有谱系均源自1983年左右发生的一次单一OPV感染,初始感染的子代在埃及沿着几条独立的传播链传播了大约十年。早期(1988年)和晚期(1993年)cVDPV分离株的完整基因组序列显示,它们的5'非翻译区(5'UTR)和非衣壳3'UTR序列源自其他C种肠道病毒。2型cVDPV的传播发生在受影响社区OPV覆盖率较低的时期,当OPV覆盖率提高时传播停止。cVDPV在对脊髓灰质炎病毒免疫力较低的人群中传播的可能性对当前和未来全球根除脊髓灰质炎的策略具有重要意义。